ADX vs. IBB, HTGC, DNP, PTY, USA, NUV, GSBD, TY, GAB, and RVT
Should you be buying Adams Diversified Equity Fund stock or one of its competitors? The main competitors of Adams Diversified Equity Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), PIMCO Corporate & Income Opportunity Fund (PTY), Liberty All-Star Equity Fund (USA), Nuveen Municipal Value Fund (NUV), Goldman Sachs BDC (GSBD), Tri-Continental (TY), The Gabelli Equity Trust (GAB), and Royce Value Trust (RVT). These companies are all part of the "investment offices, not elsewhere classified" industry.
iShares Biotechnology ETF (NASDAQ:IBB) and Adams Diversified Equity Fund (NYSE:ADX) are both mid-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, Adams Diversified Equity Fund had 1 more articles in the media than iShares Biotechnology ETF. MarketBeat recorded 4 mentions for Adams Diversified Equity Fund and 3 mentions for iShares Biotechnology ETF. Adams Diversified Equity Fund's average media sentiment score of 0.47 beat iShares Biotechnology ETF's score of 0.02 indicating that iShares Biotechnology ETF is being referred to more favorably in the media.
iShares Biotechnology ETF has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Adams Diversified Equity Fund has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
iShares Biotechnology ETF received 13 more outperform votes than Adams Diversified Equity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 53.09% of users gave Adams Diversified Equity Fund an outperform vote.
62.5% of iShares Biotechnology ETF shares are held by institutional investors. Comparatively, 28.4% of Adams Diversified Equity Fund shares are held by institutional investors. 0.1% of Adams Diversified Equity Fund shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
iShares Biotechnology ETF pays an annual dividend of $0.40 per share and has a dividend yield of 0.3%. Adams Diversified Equity Fund pays an annual dividend of $1.30 per share and has a dividend yield of 6.4%.
Given Adams Diversified Equity Fund's higher probable upside, equities research analysts plainly believe iShares Biotechnology ETF is more favorable than Adams Diversified Equity Fund.
Summary
iShares Biotechnology ETF beats Adams Diversified Equity Fund on 6 of the 11 factors compared between the two stocks.
Get Adams Diversified Equity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Adams Diversified Equity Fund Competitors List
Related Companies and Tools